中药治疗甲状腺功能减退的体外受精-胚胎移植机制:网络药理学、分子对接和分子动力学模拟的结合。

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Chang Liu, Weihuan Hu, Tianyi Zhou, Jue Zhou, Fangfang Wang, Xiaoling Feng, Fan Qu
{"title":"中药治疗甲状腺功能减退的体外受精-胚胎移植机制:网络药理学、分子对接和分子动力学模拟的结合。","authors":"Chang Liu, Weihuan Hu, Tianyi Zhou, Jue Zhou, Fangfang Wang, Xiaoling Feng, Fan Qu","doi":"10.2174/0113816128364578250212094405","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Qu's formula 6 (QUF6), a patented Chinese herbal medicine, is used to treat hypothyroidism in the context of in vitro fertilization-embryo transfer (IVF-ET). This research aims to identify the potential bioactive components and elucidate the underlying molecular mechanisms by which QUF6 cures hypothyroidism during IVF-ET.</p><p><strong>Material and methods: </strong>To find the active components of QUF6, the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and relevant literature were searched. GeneCards and other resources were used to find the targets associated with hypothyroidism and IVF-ET. Using Cytoscape software, the network of interactions was created between the targets and components, the proteinprotein interaction (PPI) network was built, and significant targets were verified. Afterward, Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed on crucial targets. Finally, molecular docking and dynamic modeling were carried out to analyze the essential components and core targets of QUF6.</p><p><strong>Results: </strong>By creating an interaction network, it was discovered that 92 active components in QUF6 can operate on 25 disease-related targets, with quercetin and other components playing important pharmacodynamic roles. Tumor necrosis factor (TNF), interleukin-6 (IL-6), interleukin-1B (IL-1B), apoptosis regulator Bcl-2 (BCL2), prostaglandin G/H synthase 2 (PTGS2), cellular tumor antigen p53 (TP53), and epidermal growth factor (EGF) were the main targets for the therapy of hypothyroidism. The KEGG pathway enrichment study identified 91 signaling pathways, whereas the GO enrichment analysis identified 1608 entries. Through molecular docking and MD simulations, stable binding was identified between the top five active constituents and the top seven potential targets.</p><p><strong>Conclusion: </strong>Quercetin, beta-sitosterol, kaempferol, 7-ketocholesterol, and rehmapicrogenin were determined to be the active ingredients in QUF6. The potential mechanism of action for QUF6 may involve modulation of TNF, IL6, IL1B, BCL2, PTSG2, TP53, and EGF to regulate oxidative stress levels, inflammation responses, and apoptosis processes associated with hypothyroidism during IVF-ET.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mechanisms of a Patented Chinese Herbal Medicine for Treating Hypothyroidism in In Vitro Fertilization-Embryo Transfer: A Combination of Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation.\",\"authors\":\"Chang Liu, Weihuan Hu, Tianyi Zhou, Jue Zhou, Fangfang Wang, Xiaoling Feng, Fan Qu\",\"doi\":\"10.2174/0113816128364578250212094405\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Qu's formula 6 (QUF6), a patented Chinese herbal medicine, is used to treat hypothyroidism in the context of in vitro fertilization-embryo transfer (IVF-ET). This research aims to identify the potential bioactive components and elucidate the underlying molecular mechanisms by which QUF6 cures hypothyroidism during IVF-ET.</p><p><strong>Material and methods: </strong>To find the active components of QUF6, the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and relevant literature were searched. GeneCards and other resources were used to find the targets associated with hypothyroidism and IVF-ET. Using Cytoscape software, the network of interactions was created between the targets and components, the proteinprotein interaction (PPI) network was built, and significant targets were verified. Afterward, Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed on crucial targets. Finally, molecular docking and dynamic modeling were carried out to analyze the essential components and core targets of QUF6.</p><p><strong>Results: </strong>By creating an interaction network, it was discovered that 92 active components in QUF6 can operate on 25 disease-related targets, with quercetin and other components playing important pharmacodynamic roles. Tumor necrosis factor (TNF), interleukin-6 (IL-6), interleukin-1B (IL-1B), apoptosis regulator Bcl-2 (BCL2), prostaglandin G/H synthase 2 (PTGS2), cellular tumor antigen p53 (TP53), and epidermal growth factor (EGF) were the main targets for the therapy of hypothyroidism. The KEGG pathway enrichment study identified 91 signaling pathways, whereas the GO enrichment analysis identified 1608 entries. Through molecular docking and MD simulations, stable binding was identified between the top five active constituents and the top seven potential targets.</p><p><strong>Conclusion: </strong>Quercetin, beta-sitosterol, kaempferol, 7-ketocholesterol, and rehmapicrogenin were determined to be the active ingredients in QUF6. The potential mechanism of action for QUF6 may involve modulation of TNF, IL6, IL1B, BCL2, PTSG2, TP53, and EGF to regulate oxidative stress levels, inflammation responses, and apoptosis processes associated with hypothyroidism during IVF-ET.</p>\",\"PeriodicalId\":10845,\"journal\":{\"name\":\"Current pharmaceutical design\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current pharmaceutical design\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0113816128364578250212094405\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128364578250212094405","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:曲方6 (QUF6)是一种专利中草药,用于治疗体外受精-胚胎移植(IVF-ET)中甲状腺功能减退症。本研究旨在鉴定其潜在的生物活性成分,并阐明QUF6治疗IVF-ET期间甲状腺功能减退的潜在分子机制。材料与方法:通过检索中药系统药理学数据库与分析平台(TCMSP)及相关文献,寻找QUF6的有效成分。GeneCards和其他资源用于寻找与甲状腺功能减退和IVF-ET相关的靶标。利用Cytoscape软件建立靶点与组分之间的相互作用网络,构建蛋白-蛋白相互作用(PPI)网络,并对重要靶点进行验证。随后,对关键靶点进行基因本体(GO)富集和京都基因与基因组百科全书(KEGG)途径分析。最后,进行分子对接和动力学建模,分析QUF6的主要成分和核心靶点。结果:通过建立相互作用网络,发现QUF6中92种活性成分可作用于25个疾病相关靶点,槲皮素等成分在其中发挥重要的药效学作用。肿瘤坏死因子(TNF)、白细胞介素-6 (IL-6)、白细胞介素- 1b (IL-1B)、凋亡调节因子Bcl-2 (BCL2)、前列腺素G/H合成酶2 (PTGS2)、细胞肿瘤抗原p53 (TP53)、表皮生长因子(EGF)是治疗甲状腺功能减退的主要靶点。KEGG通路富集研究鉴定了91个信号通路,而GO富集分析鉴定了1608个信号通路。通过分子对接和MD模拟,确定了前5种活性成分与前7种潜在靶点之间的稳定结合。结论:槲皮素、β -谷甾醇、山奈酚、7-酮胆固醇、rehmapicrogenin是QUF6的有效成分。QUF6的潜在作用机制可能涉及调节TNF、IL6、IL1B、BCL2、PTSG2、TP53和EGF,以调节IVF-ET期间与甲状腺功能减退相关的氧化应激水平、炎症反应和凋亡过程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Mechanisms of a Patented Chinese Herbal Medicine for Treating Hypothyroidism in In Vitro Fertilization-Embryo Transfer: A Combination of Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation.

Background: Qu's formula 6 (QUF6), a patented Chinese herbal medicine, is used to treat hypothyroidism in the context of in vitro fertilization-embryo transfer (IVF-ET). This research aims to identify the potential bioactive components and elucidate the underlying molecular mechanisms by which QUF6 cures hypothyroidism during IVF-ET.

Material and methods: To find the active components of QUF6, the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and relevant literature were searched. GeneCards and other resources were used to find the targets associated with hypothyroidism and IVF-ET. Using Cytoscape software, the network of interactions was created between the targets and components, the proteinprotein interaction (PPI) network was built, and significant targets were verified. Afterward, Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed on crucial targets. Finally, molecular docking and dynamic modeling were carried out to analyze the essential components and core targets of QUF6.

Results: By creating an interaction network, it was discovered that 92 active components in QUF6 can operate on 25 disease-related targets, with quercetin and other components playing important pharmacodynamic roles. Tumor necrosis factor (TNF), interleukin-6 (IL-6), interleukin-1B (IL-1B), apoptosis regulator Bcl-2 (BCL2), prostaglandin G/H synthase 2 (PTGS2), cellular tumor antigen p53 (TP53), and epidermal growth factor (EGF) were the main targets for the therapy of hypothyroidism. The KEGG pathway enrichment study identified 91 signaling pathways, whereas the GO enrichment analysis identified 1608 entries. Through molecular docking and MD simulations, stable binding was identified between the top five active constituents and the top seven potential targets.

Conclusion: Quercetin, beta-sitosterol, kaempferol, 7-ketocholesterol, and rehmapicrogenin were determined to be the active ingredients in QUF6. The potential mechanism of action for QUF6 may involve modulation of TNF, IL6, IL1B, BCL2, PTSG2, TP53, and EGF to regulate oxidative stress levels, inflammation responses, and apoptosis processes associated with hypothyroidism during IVF-ET.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
302
审稿时长
2 months
期刊介绍: Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信